Skip to Main Content
Table 1

Prognostic characteristics at entry of 142 patients with CD33 positive AML in first relapse treated with gemtuzumab ozogamicina

Study 201Study 202Study 203Study 201/202/203
Accrual 65 40 37 142 
Prior remission duration (mo)     
 Mean ± SD 16 ± 14 19 ± 22 8.7 ± 6 14.9 ± 16 
 Minimum  
Mean age ± SD 53.5 ± 16 56.6 ± 13 68.5 ± 6.3 58 ± 15 
Minimum age 18 18 60  
Prior HSCT  
Study 201Study 202Study 203Study 201/202/203
Accrual 65 40 37 142 
Prior remission duration (mo)     
 Mean ± SD 16 ± 14 19 ± 22 8.7 ± 6 14.9 ± 16 
 Minimum  
Mean age ± SD 53.5 ± 16 56.6 ± 13 68.5 ± 6.3 58 ± 15 
Minimum age 18 18 60  
Prior HSCT  
a

Study 202 allowed previous HSCT, and study 203 excluded patients under 60 years of age.

Close Modal

or Create an Account

Close Modal
Close Modal